Study highlights need for new options within heart failure treatment paradigm

Sarah Sipek | | Cardiovascular Business | Interventional Cardiology

Stealth BioTherapeutics' phase 2 study examines whether treatment for myocardial dysfunction will relieve congestive heart failure.

Elamipretide is intended for the treatment of mitochondrial dysfunction. The phase 2 study—IDDEA-HF—is a randomized, double-blind, placebo-controlled study to evaluate the cardiac and renal effects of daily treatment with elamipretide in patients who have been hospitalized with congestive heart failure.

"In heart failure, mitochondrial dysfunction may not only be a causative factor but may also contribute to the progression of the disease and the associated fluid build-up that causes congestion, due to muscle weakness from a lack of energy production," Stealth Vice President of Clinical Development Jim Carr said in a statement. "In line with our findings in elderly patients enrolled in the MOTION trial, we hope to demonstrate the ability of elamipretide to increase energy production to help the heart muscle work better, subsequently relieving congestion in the body."

Up to 300 patients will be randomized within 72 hours of presenting congestive heart failure symptoms. They will be given 20 mg daily elamipretide or placebo intravenously for up to seven days.

The primary endpoint is change in NT-proBNP, a cardiac biomarker reflecting the level of congestion. Secondary endpoints include change in clinical status and safety and tolerability.

"IDDEA-HF is a key step in our development of therapies for common diseases of aging. These patients have failed current therapies, experiencing an episode of acute decompensation, which highlights the intense need for new options within the heart failure treatment paradigm where we believe elamipretide can have a significant impact," said Reenie McCarthy, Stealth CEO. "The data from this study, together with our other ongoing trials in heart failure, will help inform our projected phase 3 heart failure program as well as our approach to other common diseases of aging for which elamipretide may have therapeutic potential."

Heart failure currently affects approximately 21 million people in the U.S. and Europe, with those numbers expected to grow as the population continues to age. 

Sarah Sipek

Related Content

Cardiologists reflect on developing primary PCI in face of criticism and pushback
How TAVR valve choice impacts outcomes when treating type 1 bicuspid AS
IVUS-guided PCI reduces risks in patients with diabetes
Medtronic using AI to identify more TAVR patients in need
SAVR linked to higher 10-year survival rate than TAVR for low-risk patients
LAAC with Watchman FLX reduces bleeding risks after AFib ablation

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."